Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ)
CNY 44.61
(0.29%)
CNY 44.61
(0.29%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 358.41 Million CNY | 0.81% |
| 2022 | 997.68 Million CNY | 11.75% |
| 2021 | 892.76 Million CNY | 40.65% |
| 2020 | 634.73 Million CNY | 15.0% |
| 2019 | 551.95 Million CNY | 19.63% |
| 2018 | 461.39 Million CNY | 43.24% |
| 2017 | 322.12 Million CNY | 20.26% |
| 2016 | 267.85 Million CNY | 32.22% |
| 2015 | 202.57 Million CNY | 54.44% |
| 2014 | 131.17 Million CNY | 119.55% |
| 2013 | 59.74 Million CNY | 8.26% |
| 2012 | 55.18 Million CNY | 50.96% |
| 2011 | 36.55 Million CNY | 51.74% |
| 2010 | 24.09 Million CNY | 39.15% |
| 2009 | 17.31 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 276.4 Million CNY | -19.36% |
| 2024 Q1 | 305.83 Million CNY | 31.26% |
| 2024 Q2 | 296.76 Million CNY | -2.97% |
| 2023 Q4 | 232.99 Million CNY | -21.54% |
| 2023 FY | 1 Billion CNY | 0.81% |
| 2023 Q1 | 282.05 Million CNY | 7.99% |
| 2023 Q2 | 287.4 Million CNY | 1.9% |
| 2023 Q3 | 296.96 Million CNY | 3.32% |
| 2022 Q2 | 249.48 Million CNY | -0.5% |
| 2022 FY | 997.68 Million CNY | 11.75% |
| 2022 Q4 | 261.19 Million CNY | 10.55% |
| 2022 Q3 | 236.25 Million CNY | -5.3% |
| 2022 Q1 | 250.75 Million CNY | 1.87% |
| 2021 Q2 | 216.44 Million CNY | 11.56% |
| 2021 Q1 | 194.01 Million CNY | 6.4% |
| 2021 Q3 | 236.16 Million CNY | 9.11% |
| 2021 Q4 | 246.14 Million CNY | 4.23% |
| 2021 FY | 892.76 Million CNY | 40.65% |
| 2020 Q1 | 141.7 Million CNY | -16.5% |
| 2020 Q3 | 157.11 Million CNY | 2.32% |
| 2020 FY | 634.73 Million CNY | 15.0% |
| 2020 Q4 | 182.35 Million CNY | 16.07% |
| 2020 Q2 | 153.55 Million CNY | 8.36% |
| 2019 Q4 | 169.7 Million CNY | 29.72% |
| 2019 FY | 551.95 Million CNY | 19.63% |
| 2019 Q3 | 130.82 Million CNY | 4.7% |
| 2019 Q2 | 124.95 Million CNY | -1.2% |
| 2019 Q1 | 126.47 Million CNY | -2.12% |
| 2018 Q1 | 107.82 Million CNY | 16.37% |
| 2018 Q4 | 129.2 Million CNY | 11.99% |
| 2018 FY | 461.39 Million CNY | 43.24% |
| 2018 Q3 | 115.37 Million CNY | 5.86% |
| 2018 Q2 | 108.98 Million CNY | 1.08% |
| 2017 Q3 | 82.03 Million CNY | 21.34% |
| 2017 Q4 | 92.65 Million CNY | 12.94% |
| 2017 FY | 322.12 Million CNY | 20.26% |
| 2017 Q1 | 79.81 Million CNY | 9.48% |
| 2017 Q2 | 67.6 Million CNY | -15.29% |
| 2016 Q2 | 58.44 Million CNY | -11.71% |
| 2016 Q3 | 70.31 Million CNY | 20.32% |
| 2016 FY | 267.85 Million CNY | 32.22% |
| 2016 Q4 | 72.9 Million CNY | 3.68% |
| 2016 Q1 | 66.18 Million CNY | 47.04% |
| 2015 Q4 | 45.01 Million CNY | -16.3% |
| 2015 Q2 | 49.27 Million CNY | -9.59% |
| 2015 Q1 | 54.5 Million CNY | 36.22% |
| 2015 FY | 202.57 Million CNY | 54.44% |
| 2015 Q3 | 53.77 Million CNY | 9.13% |
| 2014 Q4 | 40.01 Million CNY | -5.81% |
| 2014 Q3 | 42.48 Million CNY | 77.66% |
| 2014 Q2 | 23.91 Million CNY | -3.45% |
| 2014 FY | 131.17 Million CNY | 119.55% |
| 2014 Q1 | 24.76 Million CNY | 34.66% |
| 2013 Q2 | 13.66 Million CNY | -3.04% |
| 2013 FY | 59.74 Million CNY | 8.26% |
| 2013 Q4 | 18.39 Million CNY | 35.32% |
| 2013 Q3 | 13.59 Million CNY | -0.57% |
| 2013 Q1 | 14.09 Million CNY | -6.49% |
| 2012 Q2 | 11.83 Million CNY | 3.62% |
| 2012 FY | 55.18 Million CNY | 50.96% |
| 2012 Q4 | 15.07 Million CNY | -10.59% |
| 2012 Q3 | 16.86 Million CNY | 42.51% |
| 2012 Q1 | 11.41 Million CNY | 23.15% |
| 2011 Q3 | 10.38 Million CNY | 0.0% |
| 2011 FY | 36.55 Million CNY | 51.74% |
| 2011 Q4 | 9.27 Million CNY | -10.68% |
| 2010 FY | 24.09 Million CNY | 39.15% |
| 2009 FY | 17.31 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 3.35 Billion CNY | 89.31% |
| Dirui Industrial Co.,Ltd. | 387.16 Million CNY | 7.425% |
| Beijing Strong Biotechnologies, Inc. | 702.74 Million CNY | 48.998% |
| Medicalsystem Biotechnology Co., Ltd. | 562.06 Million CNY | 36.232% |
| Maccura Biotechnology Co.Ltd | 1.18 Billion CNY | 69.636% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.17 Billion CNY | 69.507% |
| Guangdong Hybribio Biotech Co.,Ltd. | 631.43 Million CNY | 43.238% |
| BGI Genomics Co., Ltd. | 1.93 Billion CNY | 81.518% |
| Amoy Diagnostics Co., Ltd. | 574.96 Million CNY | 37.663% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 479.96 Million CNY | 25.325% |